Molecular aspects of estrogen receptor variants in breast cancer Suzanne A. W. FuquaDouglas M. Wolf San Antonio Breast Cancer Symposium — plenary lecture Pages: 233 - 241
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer Rosario Vincenzo IaffaioliAnna TortorielloFrancesco Caponigro Report Pages: 243 - 248
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer Robin MurrayPaula Pitt Report Pages: 249 - 253
Nonattendance in the Stockholm mammography screening trial: Relative Mortality and reasons for nonattendance E. LidbrinkJ. FrisellL. -E. Rutqvist Report Pages: 267 - 275
Increased phosphotyrosine in breast cancer tissue is associated with a worse prognosis Elyse E. LowerMary Ann MillerSue Heffelfinger Report Pages: 277 - 282
The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases Nathalie QuénelJean WafflartJean-Michel Coindre Report Pages: 283 - 291
Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas Nicola NormannoNancy KimDavid S. Salomon Brief Communication Pages: 293 - 297
